Luigi Messori

Prof. Luigi Messori

Laboratory of Metals in Medicine (MetMed), Department of Chemistry, University of Florence, Via della Lastruccia 3, Sesto Fiorentino, Italy
orcid

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2009 in Coordination Chemistry Reviews
Verified
Journal Article
Closed access
ABAlberto Bindoli
Alberto Bindoli
MRMaria Pia Rigobello
Maria Pia Rigobello
GSGuido Scutari
Guido Scutari
Chiara GabbianiChiara Gabbiani
Chiara Gabbiani
ACAngela Casini
Angela Casini
Luigi MessoriLuigi Messori
Luigi Messori

24 July 2009 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
Stefania NobiliStefania Nobili
Stefania Nobili
Enrico MiniEnrico Mini
Enrico Mini
ILIda Landini
Ida Landini
Chiara GabbianiChiara Gabbiani
Chiara Gabbiani
ACAngela Casini
Angela Casini
Luigi MessoriLuigi Messori
Luigi Messori

24 May 2019 in Molecules
Verified
Journal Article
Open access
PDF file
EAEnzo Alessio
Enzo Alessio
Luigi MessoriLuigi Messori
Luigi Messori
NAMI-A ((ImH)[trans-RuCl4(dmso-S)(Im)], Im = imidazole) and KP1019/1339 (KP1019 = (IndH)[trans-RuCl4(Ind)2], Ind = indazole; KP1339 = Na[trans-RuCl4(Ind)2]) are two structurally related ruthenium(III) coordination compounds that have attracted a lot of attention in the medicinal inorganic chemistry scientific community as promising anticancer drug candidates. This has led to a considerable amount of studies on their respective chemico-biological features and to the eventual admission of both to clinical trials. The encouraging pharmacological performances qualified KP1019 mainly as a cytotoxic agent for the treatment of platinum-resistant colorectal cancers, whereas the non-cytotoxic NAMI-A has gained the reputation of being a very effective antimetastatic drug. A critical and strictly comparative analysis of the studies conducted so far on NAMI-A and KP1019 allows us to define the state of the art of these experimental ruthenium drugs in terms of the respective pharmacological profiles and potential clinical applications, and to gain some insight into the inherent molecular mechanisms. Despite their evident structural relatedness, deeply distinct biological and pharmacological profiles do emerge. Overall, these two iconic ruthenium complexes form an exemplary and unique case in the field of medicinal inorganic chemistry.

1 September 2000 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Luigi MessoriLuigi Messori
Luigi Messori
FAFrancesco Abbate
Francesco Abbate
GMGiordana Marcon
Giordana Marcon
POPierluigi Orioli
Pierluigi Orioli
MFMarco Fontani
Marco Fontani
PZPiero Zanello
Piero Zanello

29 May 2004 in Inorganic Chemistry
Verified
Journal Article
Closed access
MVMassimo Di Vaira
Massimo Di Vaira
CBCarla Bazzicalupi
Carla Bazzicalupi
POPierluigi Orioli
Pierluigi Orioli
Luigi MessoriLuigi Messori
Luigi Messori
BBBruno Bruni
Bruno Bruni
PZPaolo Zatta
Paolo Zatta

13 March 2002 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GMGiordana Marcon
Giordana Marcon
SCStefania Carotti
Stefania Carotti
MCMarcella Coronnello
Marcella Coronnello
Luigi MessoriLuigi Messori
Luigi Messori
Enrico MiniEnrico Mini
Enrico Mini
GMGiovanni Minghetti
Giovanni Minghetti